<section class="Section" data-sectioncode="34089-3"><a name="S11"></a><a name="section-8"></a><p></p><h1>11 DESCRIPTION</h1><p class="First">Erenumab-aooe is a human immunoglobulin G2 (IgG2) monoclonal antibody that has high affinity binding to the calcitonin gene-related peptide receptor. Erenumab-aooe is produced using recombinant DNA technology in Chinese hamster ovary (CHO) cells. It is composed of 2 heavy chains, each containing 456 amino acids, and 2 light chains of the lambda subclass, each containing 216 amino acids, with an approximate molecular weight of 150 kDa.</p><p>AIMOVIG (erenumab-aooe) injection is supplied as a sterile, preservative-free, clear to opalescent, colorless to light yellow solution for subcutaneous administration. Each 1 mL 70 mg single-dose prefilled autoinjector and 70 mg single-dose prefilled glass syringe contains 70 mg erenumab-aooe, acetate (1.5 mg), polysorbate 80 (0.10 mg), and sucrose (73 mg). Each 1 mL 140 mg single-dose prefilled autoinjector and 140 mg single-dose prefilled glass syringe contains 140 mg erenumab-aooe, acetate (2.0 mg), polysorbate 80 (0.10 mg), and sucrose (65 mg). Enclosed within the autoinjector is a single-dose, prefilled glass syringe. The solution of AIMOVIG has a pH of 5.2.</p></section>

AIMOVIG

erenumab

erenumab-aooe

1 ML erenumab-aooe 70 MG/ML Prefilled Syringe

Aimovig

1 ML erenumab-aooe 70 MG/ML Prefilled Syringe [Aimovig]

1 ML erenumab-aooe 70 MG/ML Auto-Injector

1 ML erenumab-aooe 70 MG/ML Auto-Injector [Aimovig]

1 ML erenumab-aooe 140 MG/ML Auto-Injector

1 ML erenumab-aooe 140 MG/ML Auto-Injector [Aimovig]

1 ML erenumab-aooe 140 MG/ML Prefilled Syringe

1 ML erenumab-aooe 140 MG/ML Prefilled Syringe [Aimovig]

Psoriasis (PsO)

Psoriatic Arthritis (PsA)

Ankylosing Spondylitis (AS)

Nonradiographic Axial Spondyloarthritis

Taltz

Juvenile Idiopathic Arthritis

Hidradenitis Suppurativa (HS)

Cosentyx

Siliq

Tremfya

Crohn's Disease (CD)

Ulcerative Colitis (UC)

Stelara

Skyrizi

Ilumya

Migraine

Cluster Headache

Migraine Prevention

Emgality

Qulipta

Acute Migraine

Ubrelvy

Nurtec ODT

Vyepti

Ajovy

Breast Cancer: HR+ (HER2-)

Verzenio

Ibrance

Kisqali

Atopic Dermatitis (Eczema)

Cibinqo

Eucrisa

Asthma (injectable)

Asthma OCS Dependent

Nasal Polyposis

Eosinophilic Esophagitis (EoE)

Prurigo Nodularis

Dupixent

Opzelura

Adbry

NSCLC ALK+ OR ROS1+ Disease

Lorbrena

Alecensa

Alunbrig

NSCLC cMET Mutation

Xalkori

Rheumatoid Arthritis (RA)

Xeljanz

Uveitis

Graft Versus Host Disease (GVHD)

Orencia

COVID-19 Treatment

Alopecia Areata

Olumiant

Multiple Sclerosis (MS)

Secondary Progressive Multiple Sclerosis

Zeposia

Rinvoq

Entyvio

Aimovig is a prescription medication that adults can self-inject once a month under the skin to prevent migraine headaches. The most common side effects are injection site reactions and constipation. However, there are no reported instances of drug interactions with Aimovig.

Aimovig is FDA approved for the following indications: Migraine prevention. 


Report Adverse Event 

Prescribing Information

Prescribing Information - Spanish

Medication Guide: Latex containing Pen 

Medication Guide: Non-Latex Pen 

Submit MSL Request 

Pharmacy List 

Online Sample Form [Connect With A Rep Pop-Up]

Coverage Authorization Request 

Coverage Authorization Appeals

Letter of Medical Necessity 

PA Checklist 

Enroll in Patient Savings Program 

Other HCP Resources 

About Aimovig 

Taking Aimovig

Side Effects

Patient Stories 

AimAlly Support Program 

Patient Resources 

Aimovig Start Guide 

Doctor Discussion Guide 

Instructions For Use (Video): Migraine Prevention 

Instructions For Use [Prefilled SureClick Autoinjector 70mg/ml]: Migraine Prevention 

Instructions For Use [Prefilled SureClick Autoinjector 140 mg/mL]: Migraine Prevention 